Scopus BioPharma Inc. (Nasdaq: “SCPS”) today announced the approval of an investigational new drug application (“IND”) by the United States Food and Drug Administration (“FDA”) for CpG-STAT3siRNA, the company’s distinctive immuno-oncology RNA therapy for the treatment of multiple cancers.
A Phase 1 clinical trial for B-cell non-Hodgkin lymphoma will be initiated at City of Hope.
https://finance.yahoo.com/news/scopus-biopharma-announces-fda-approval-133000399.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.